| Ytd | 95.65% | |
| 1y | 104.55% |
| Open | 2.27 | Prev Close | 2.29 | Low | 2.19 | High | 2.29 | Mkt Cap | 1.00B |
| Vol | 6.65M | Avg Vol | 3.28M | EPS | -0.16 | P/E | N/A | Forward P/E | -11.80 |
| Beta | 1.03 | Short Ratio | 11.53 | Inst. Own | 83.69% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-05 | 50-d Avg | 2.32 | 200-d Avg | 1.77 | 1yr Est | 3.86 |
LXRX News
Findings presented at ESC Congress 2026 and simultaneously published in JACC: Heart Failure Findings
LX9851 is a first-in-class, oral non-incretin candidate being developed by Novo Nordisk for the trea
Lexicon Pharmaceuticals (LXRX) is nearing multiple potential value-transforming events for sotaglifl
Lexicon Pharmaceuticals NASDAQ: LXRX reported a wider second-quarter loss as revenue declined sharpl
Lexicon Pharmaceuticals, Inc. (LXRX) Q2 2026 Earnings Call Transcript
Lexicon Pharmaceuticals (LXRX) came out with a quarterly loss of $0.06 per share in line with the Za
Lexicon Pharmaceuticals (NASDAQ:LXRX) reported quarterly losses of $(0.07) per share which missed th
Enrollment complete in Phase 3 SONATA-HCM study; top-line data expected Q1 2027 NDA resubmission ac
THE WOODLANDS, Texas, July 30, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX)
The study substantially exceeded its enrollment target of 500 patients across more than 130 sites in
Study substantially exceeded enrollment target of 500 patients Topline results anticipated in Q1 202
Lexicon advances sotagliflozin into new indications while its obesity and pain programs progress, se
One company posts rapid revenue growth but remains unprofitable, while the other boasts global scale
Presentations highlight consistent A1c reductions with sotagliflozin in type 1 diabetes and pharmaco
THE WOODLANDS, Texas, May 28, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX)
THE WOODLANDS, Texas, May 12, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX)
Citigroup analyst Yigal Nochomovitz maintains Lexicon Pharmaceuticals (NASDAQ:LXRX) with a Buy an
Lexicon Pharmaceuticals NASDAQ: LXRX executives highlighted progress across late-stage regulatory pr
Lexicon Pharmaceuticals, Inc. (LXRX) Q1 2026 Earnings Call Transcript
Lexicon Pharmaceuticals (LXRX) reported break-even quarterly earnings per share versus the Zacks Con
Lexicon Pharmaceuticals (NASDAQ:LXRX) reported quarterly sales of $1.090 million which missed the an
SONATA-HCM anticipated to be fully enrolled mid-2026 Resubmission of NDA for ZYNQUISTA ® in type 1
THE WOODLANDS, Texas, May 04, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX)
THE WOODLANDS, Texas, April 30, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that results from its PROGRESS Phase 2b
U.S. stock futures up, Dow gains 150 points. Avis Budget Group (CAR) shares fall 9.6% in pre-market.
HC Wainwright & Co. analyst Joseph Pantginis reiterates Lexicon Pharmaceuticals (NASDAQ:LXRX)
In March 2025, Lexicon signed an exclusive license agreement with Novo Nordisk for LX9851 in obesity
- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced that results of a post hoc analysis of
HC Wainwright & Co. analyst Joseph Pantginis maintains Lexicon Pharmaceuticals (NASDAQ:LXRX)
U.S. stock futures were higher this morning, with the Dow futures gaining more than 100 points on Mo
U.S. stock futures fell on Monday after three consecutive days of decline on Friday. Futures of benc